ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it has enrolled 322 adult patients (236 confirmed respiratory disease cases and 86 control cases) in its first adult study at Joondalup Health Campus. Enrolment at the Wesley Emergency Centre in Brisbane, Australia has recently started which will significantly increase the rate of enrolment and greatly expand the range of respiratory illnesses captured.
The study at the Wesley Emergency Centre is also ResApp’s first clinical site to perform electronic data collection using Apple iPads which will increase the speed of data verification and analysis.
“We are very pleased with the rate of patient enrolment at Joondalup. At that one site we are already close to achieving our initial target total enrolment of 400 adult patients and with the Wesley also recruiting patients we expect to exceed our initial target shortly,” said Dr Tony Keating, Managing Director and CEO of ResApp. “We are now looking towards the first preliminary analysis of the adult data which is on track to be released by the end of this quarter.”
A copy of today’s press release by the Wesley Hospital can be downloaded here.
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has a paediatric multi-site clinical study underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. ResApp recently initiated a multi-site clinical study in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.